info:eu-repo/semantics/article
Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model
Fecha
2014-09Registro en:
Renna, Nicolas Federico; Diez, Emiliano Raúl; Miatello, Roberto Miguel; Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model; Public Library of Science; Plos One; 9; 9; 9-2014; 1-8
1932-6203
CONICET Digital
CONICET
Autor
Renna, Nicolas Federico
Diez, Emiliano Raúl
Miatello, Roberto Miguel
Resumen
Background
In this study, we used vidagliptin(V) to examine the role of the DDP-IV, incretin system component, in the activation of different molecular inflammatory cytokines, NF-kB and VCAM-1 to generate a microenvironment that supports cardiovascular remodeling.
Methods
Male WKY and SHR were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+V: (5 mg/kg per day for 6 weeks) (n = 8 each group). Metabolic variables and systolic blood pressure were measured. The TBRAS, eNOS activity, and NAD(P)H oxidase activity were estimated to evaluate oxidative stress. Cardiac and vascular remodeling were evaluated. To assess the cytokine, NF-kB and VCAM-1 immunostaining techniques were used.
Results
The FFHR experimental model presents metabolic syndrome criteria, vascular and cardiac remodeling, vascular inflammation due to increased expression of NF-kB, VCAM-1, and pro-atherogenic cytokines. Chronic treatment with V was able to reverse total or partiality of variables studied.
Conclusions
Data demonstrated an important effect of DDP-IV in reducing vascular inflammation, accompanied by a favorable reduction in metabolic and structural parameters.